Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. PTC
2. NVDA
3. PCVX
4. SPY
5. META
6. USO
7. MSFT
8. AMD
9. AMZN
10. ATH

Go back to Syros Pharmaceuticals (SYRS) Tops Q1 EPS by 7c

Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update

May 16, 2022 7:30 AM EDT

Three Data Readouts Expected in 2022:

Data from the Safety Lead-ins of the SY-5609 Trial in Pancreatic Cancer and of the SELECT-AML-1 Phase 2 Trial; Data from the Dose Confirmation Study of SY-2101 in APL

On Track to Report Data from Ongoing SELECT-MDS-1 Pivotal Trial in Q4 2023/Q1 2024

Management to Host Conference Call at 8:30 a.m. ET Today

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the... More